{
  "1TM.F": {
    "city": "LiÃ¨ge",
    "country": "Belgium",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Mithra Pharmaceuticals SA",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "MITHRA PHARMACEUTIC.AIW",
    "state": null,
    "summary": "Mithra Pharmaceuticals SA develops, manufactures, and markets complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers in Europe and internationally. Its development candidates include Estelle, which has completed phase III clinical trial is a combined oral contraceptive; Donesta, which is in phase III clinical trial for vasomotor menopausal symptoms relief; and PeriNesta, an oral treatment for perimenopause. The company also develops Myring, a contraceptive vaginal ring releasing a combination of hormones; Zoreline, a biodegradable subcutaneous implant for use in prostate and breast cancers, and benign gynecological indications; and Tibelia, a solution for treating menopause and osteoporosis. Mithra Pharmaceuticals SA was founded in 1999 and is headquartered in LiÃ¨ge, Belgium.",
    "website": "http://www.mithra.com",
    "zipcode": "4000"
  },
  "4A5.F": {
    "city": "Nazareth",
    "country": "Belgium",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Fagron NV",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "FAGRON N.V. PORT.",
    "state": null,
    "summary": "Fagron NV, a pharmaceutical compounding company, provides personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients. It prepares personalized ready-to-use medication in its sterile and non-sterile compounding facilities. The company also innovates concepts, vehicles, and formulations for pharmaceutical compounding. In addition, it offers pharmaceutical raw materials, equipment, and supplies that pharmacists need to prepare medication in the pharmacy. Further, the company develops, manufactures, and supplies mixing equipment that pharmacists can use for the compounding of semi-solid dermatological formulations. It has operations in Europe, the Americas, the Middle East, and Africa, as well as Asia and the Pacific. The company was formerly known as Arseus NV and changed its name to Fagron NV in January 2015. Fagron NV was founded in 1990 and is based in Nazareth, Belgium.",
    "website": "http://www.fagron.com",
    "zipcode": "9810"
  },
  "FAGR.BR": {
    "city": "Nazareth",
    "country": "Belgium",
    "currency": "EUR",
    "exchange": "BRU",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Fagron NV",
    "market": "be_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "FAGRON",
    "state": null,
    "summary": "Fagron NV, a pharmaceutical compounding company, provides personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients. It prepares personalized ready-to-use medication in its sterile and non-sterile compounding facilities. The company also innovates concepts, vehicles, and formulations for pharmaceutical compounding. In addition, it offers pharmaceutical raw materials, equipment, and supplies that pharmacists need to prepare medication in the pharmacy. Further, the company develops, manufactures, and supplies mixing equipment that pharmacists can use for the compounding of semi-solid dermatological formulations. It has operations in Europe, the Americas, the Middle East, and Africa, as well as Asia and the Pacific. The company was formerly known as Arseus NV and changed its name to Fagron NV in January 2015. Fagron NV was founded in 1990 and is based in Nazareth, Belgium.",
    "website": "http://www.fagron.com",
    "zipcode": "9810"
  },
  "MITPF": {
    "city": "LiÃ¨ge",
    "country": "Belgium",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Mithra Pharmaceuticals SA",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "MITHRA PHARMACEUTICALS SA NV",
    "state": null,
    "summary": "Mithra Pharmaceuticals SA develops, manufactures, and markets complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers in Europe and internationally. Its development candidates include Estelle, which has completed phase III clinical trial is a combined oral contraceptive; Donesta, which is in phase III clinical trial for vasomotor menopausal symptoms relief; and PeriNesta, an oral treatment for perimenopause. The company also develops Myring, a contraceptive vaginal ring releasing a combination of hormones; Zoreline, a biodegradable subcutaneous implant for use in prostate and breast cancers, and benign gynecological indications; and Tibelia, a solution for treating menopause and osteoporosis. Mithra Pharmaceuticals SA was founded in 1999 and is headquartered in LiÃ¨ge, Belgium.",
    "website": "http://www.mithra.com",
    "zipcode": "4000"
  },
  "MITRA.BR": {
    "city": "LiÃ¨ge",
    "country": "Belgium",
    "currency": "EUR",
    "exchange": "BRU",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Mithra Pharmaceuticals SA",
    "market": "be_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "MITHRA",
    "state": null,
    "summary": "Mithra Pharmaceuticals SA develops, manufactures, and markets complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers in Europe and internationally. Its development candidates include Estelle, which has completed phase III clinical trial is a combined oral contraceptive; Donesta, which is in phase III clinical trial for vasomotor menopausal symptoms relief; and PeriNesta, an oral treatment for perimenopause. The company also develops Myring, a contraceptive vaginal ring releasing a combination of hormones; Zoreline, a biodegradable subcutaneous implant for use in prostate and breast cancers, and benign gynecological indications; and Tibelia, a solution for treating menopause and osteoporosis. Mithra Pharmaceuticals SA was founded in 1999 and is headquartered in LiÃ¨ge, Belgium.",
    "website": "http://www.mithra.com",
    "zipcode": "4000"
  }
}
